Video
Author(s):
Thomas Hope, MD, discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.
Thomas Hope, MD, an associate professor of radiology and director of Molecular Therapy for the Molecular Imaging and Therapeutics Clinical Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco (UCSF), discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.
A prospective phase 3 trial evaluated the sensitivity and specificity of the radiotracer 68Ga-PSMA-11 in detecting pelvic nodal metastases at the time of radical prostatectomy in men with intermediate- or high-risk prostate cancer.
Previously published data from Europe demonstrated the utility of Ga68-PSMA-11 in this setting, says Hope.
Positive findings from this study support the utility of this radiotracer, as well as the submission of a New Drug Application to the FDA, concludes Hope.